Summary: Listening to Mozart’s “Sonata for Two Pianos in D Major, K. 448” daily may reduce seizure activity for those with epilepsy.
Source: University Health Network
A new clinical research study by Dr. Marjan Rafiee and Dr. Taufik Valiante of the Krembil Brain Institute at Toronto Western Hospital, part of University Health Network, has found that a Mozart composition may reduce seizure frequency in patients with epilepsy.
The results of the research study, “The Rhyme and Rhythm of Music in Epilepsy,” was recently published in the international journal Epilepsia Open. It looks at the effects of the Mozart melody, “Sonata for Two Pianos in D Major, K. 448” on reducing seizures, as compared to another auditory stimulus – a scrambled version of the original Mozart composition, with similar mathematical features, but shuffled randomly and lacking any rhythmicity.
“In the past 15 to 20 years, we have learned a lot about how listening to one of Mozart’s compositions in individuals with epilepsy appears to demonstrate a reduction in seizure frequency,” says Dr. Marjan Rafiee, lead author on the study. “But, one of the questions that still needed to be answered was whether individuals would show a similar reduction in seizure frequency by listening to another auditory stimulus – a control piece – as compared to Mozart.”
The researchers recruited 13 patients to participate in the novel, year-long study. After three months of a baseline period, half of the patients listened to Mozart’s Sonata once daily for three months, then switched to the scrambled version for three months. The others started the intervention by listening to the scrambled version for three months, then switched to daily listening of Mozart.
Patients kept “seizure diaries” to document their seizure frequency during the intervention. Their medications were kept unchanged during the course of the study.
“Our results showed daily listening to the first movement of Mozart K.448 was associated with reducing seizure frequency in adult individuals with epilepsy,” says Dr. Rafiee. “This suggests that daily Mozart listening may be considered as a supplemental therapeutic option to reduce seizures in individuals with epilepsy.”
Epilepsy is the most common serious neurological disorder in the world, affecting approximately 300,000 Canadians and 50 million people worldwide.
Many experience debilitating seizures. The treatment is often one or more anti-seizure medications. But for 30 per cent of patients, the medications are not effective in controlling their seizures.
“As a surgeon, I have the pleasure of seeing individuals benefit from surgery, however I also know well those individuals for whom surgery is not an option, or those who have not benefitted from surgery, so, we are always looking for ways to improve symptom control, and improve quality of life for those with epilepsy,” says Dr. Taufik Valiante, senior author of the study and the Director of the Surgical Epilepsy Program at Krembil Brain Institute at UHN and co-Director of CRANIA.
“Like all research, ours raises a lot of questions that we are excited to continue to answer with further research and support from the epilepsy community.”
While these results are promising, the next step is to conduct larger studies with more patients, over a longer period of time.
Funding: This work is supported by Epilepsy Ontario and the Toronto General & Western Hospital Foundation.
For more information on the project, or to learn about research updates, please visit: http://www.neurontobrainlaboratory.ca/music-therapy-login.
About this neuroscience research article
University Health Network
Heather Sherman – University Health Network
The image is in the public domain.
Original Research: Open access
“Daily listening to Mozart reduces seizures in individuals with epilepsy: A randomized control study”. by Marjan Rafiee, Kramay Patel, David M. Groppe, Danielle M. Andrade, Eduard Bercovici, Esther Bui, Peter L. Carlen, Aylin Reid, Peter Tai, Donald Weaver, Richard Wennberg, Taufik A. Valiante.
Epilepsia Open doi:10.1002/epi4.12400
Daily listening to Mozart reduces seizures in individuals with epilepsy: A randomized control study
Epilepsy is one of the most common neurological disorders . Many individuals continue to have seizures despite medical and surgical treatments, suggesting adjunctive management strategies are required. Promising effects of daily listening to Mozart on reducing seizure frequency in individuals with epilepsy have been demonstrated over the last 20 years, but not in a rigorously controlled manner. In this study, we compared the effect on seizure frequency of daily listening to either Mozart K.448 or a spectrally similar, yet non‐rhythmic control piece. We hypothesized that there would be no difference in seizure counts when participants listened to Mozart K.448 vs when they listened to the control piece.
We employed a randomized crossover design, in which each participant was exposed to both three months of daily listening to the first six minutes of Sonata for two pianos in D major by Mozart (Mozart K.448; treatment period) and three months of daily listening to phase‐scrambled version (control period). There was a three‐month baseline and a three‐month follow‐up period before and after the six‐month listening period, respectively. Change in seizure counts obtained from the seizure diaries was considered as the main study outcome.
Using three methodologies to investigate the existence of the treatment effect (paired t test, estimation statistics and plots, and Cohen’s d ), our results revealed a reduction in seizure counts during the treatment period, which was not observed for the control period (P‐value < .001).
Using a spectrally similar control piece, our study advances previous reports that were limited by a “no music” control condition. Daily listening to Mozart K.448 was associated with reducing seizure frequency in adult individuals with epilepsy. These results suggest that daily Mozart listening may be considered as an adjunctive therapeutic option to reduce seizure burden in individuals with epilepsy.
Feel Free To Share This Neuroscience News.